Answers are grounded in this paper and cite their sources.
The current study is based on design and optimization of novel valsartan and sacubitril complex (VAL-SAC) 250 mg gastro-retentive controlled-release floating tablet using HPMC K15M and Carbopol 971. The drug combination is recommended for the treatment of symptomatic chronic heart failure (NYHA Class II-IV) with reduced ejection fraction. The prolong gastric residence time helps in reducing the frequency of administration and ensuring sustained control up to 24 h. The compression attributes were determined by Heckel analysis and USP 1062. A Quality by Design (QbD)- based risk assessment was performed to identify the Critical Quality Attributes (CQAs) and critical variables. The high-risk score was determined for buoyancy parameters (floating lag time, total floating time, swelling index) and in vitro drug release at 1, 12, and 24 h, relative to HPMC K15M and Carbopol 971, as CMAs. The compression analysis revealed yield pressure of 161 MPa for tablet formation. A Central Composite Design (CCD) was used to generate the experimental design and design space via numerical optimization. The optimized formulation (F opt ) was characterized by buoyancy parameters, in vitro drug release, surface morphology, chemical interactions, and thermal stability by SEM, FTIR, and DSC, respectively. F opt released > 90% of the complex within 24 h and was found to be stable, with a shelf life of 16 months. In silico PBPK modeling using GastroPlus™ yielded PK parameters and bioavailability values comparable to the reported data. The controlled-release gastro-retentive floating tablets of (VAL-SAC) complex were formulated successfully using the combined effect of swelling and rate-controllable polymers.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: